Stockreport

CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver...

CymaBay Therapeutics Inc.  (CBAY) 
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cymabay.com
PDF 52-week analysis highlights the potential for seladelpar to offer patients improved efficacy and better tolerability than existing second line treatmentThird consecutive [Read more]